logo-loader

Tiziana Life Sciences: A different approach, tackling disease using a safe, nasal and oral antibody

Published: 04:58 22 Sep 2021 EDT

Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come. 


The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal surfaces aiming to modulate the immune response. Savin says this might help to control various autoimmune diseases such as Crohn’s and Multiple Sclerosis (MS).


Foralumab has also been clinically tested with interesting results in COVID-19 patients to alleviate any immune overreaction. Mucosal delivery is an innovative approach and foralumab is in early-stage clinical development.

 

Read Dr John Savin's outlook report: Controlling disease using a safe, nasal and oral antibody

Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive...

on 10/16/2023